Abstract:Interactions between the gut microbiota and host immunity are sophisticated, dynamic, and host-dependent. Scientists have recently conducted research showing that disturbances in the gut bacterial community can lead to a decrease in some metabolites and, consequently, to behaviors such as depression. Exposure to stressors dropped the relative abundance of bacteria in the genus Bacteroides while soaring the relative abundance of bacteria in the genus Clostridium, Coprococcus, Dialister, and Oscillibacter, which were also reduced in people with depression. Microbiota and innate immunity are in a bilateral relationship. The gut microbiota has been shown to induce the synthesis of antimicrobial proteins such as catalysidins, type C lectins, and defensins. Probiotic bacteria can modulate depressive behavior through GABA signaling. The gut microbiome produces essential metabolites such as neurotransmitters, tryptophan metabolites, and short-chain fatty acids (SCFAs) that can act on the CNS. In the case of dysbiosis, due to mucin changes, the ratio of intestinal-derived molecules may change and contribute to depression. Psychotropics, including Bifidobacterium longum NCC3001, Clostridium butyricum CBM588, and Lactobacillus acidophilus, have mental health benefits, and can have a positive effect on the host-brain relationship, and have antidepressant effects. This article reviews current studies on the association between gut microbiota dysbiosis and depression. Comprehensively, these findings could potentially lead to novel approaches to improving depressive symptoms via gut microbiota alterations, including probiotics, prebiotics, and fecal microbiota transplantation.

Gut microbiota and its metabolites in depression: from pathogenesis to treatment

Epigenetics in depression and gut-brain axis: A molecular crosstalk

Depression-associated gut microbes, metabolites and clinical trials

Gut Microbial Clues to Bipolar Disorder: State‐of‐the‐art Review of Current Findings and Future Directions

Mechanistic Insights into the Link between Gut Dysbiosis and Major Depression: An Extensive Review

Reviewing the role of gut microbiota in the pathogenesis of depression and exploring new therapeutic options

The Microbiota–Gut–Brain Axis in Depression: The Potential Pathophysiological Mechanisms and Microbiota Combined Antidepression Effect

Impacts of microbiota and its metabolites through gut-brain axis on pathophysiology of major depressive disorder

Baseline gut microbiota profiles affect treatment response in patients with depression

The Gut Microbiota and Major Depressive Disorder: Current Understanding and Novel Therapeutic Strategies

Probiotics for the treatment of depression and its comorbidities: A systemic review

Potential role of gut microbiota in major depressive disorder: A review

Gut Microbiota Metabolites in Major Depressive Disorder—Deep Insights into Their Pathophysiological Role and Potential Translational Applications

Current landscape of fecal microbiota transplantation in treating depression

The role of microbiota in the pathogenesis of schizophrenia and major depressive disorder and the possibility of targeting microbiota as a treatment option

Characteristics of gut microbiota and metabolic phenotype in patients with major depressive disorder based on multi-omics analysis

New perspectives on microbiome-dependent gut-brain pathways for the treatment of depression with gastrointestinal symptoms: from bench to bedside

Research progress on intestinal flora and depression

Gut microbiota-derived short-chain fatty acids and depression: deep insight into biological mechanisms and potential applications

Progress in the Application of Intestinal Flora in the Treatment of Depression

role of the gut microbiota in pathogenesis and treatment of depression